Virtual Library

Start Your Search

Thierry Landre

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      165P - Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis (ID 383)

      12:30 - 13:00  |  Presenting Author(s): Thierry Landre

      • Abstract
      • Slides


      First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Combination of anti-PD-1/PD-L1 to chemotherapy (CT) offers a new therapeutic option for this population.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      We performed a meta-analysis of randomized trials that compared PD-1/PD-L1 inhibitor plus CT with CT alone in first line of treatment for advanced NSCLC. The outcomes included overall survival (OS), progression-free survival (PFS) and objective response rate (ORR). A fixed-effect or random-effects model was adopted depending on between-study heterogeneity.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      The eight eligible studies included 4401 patients (3097 males, mostly smokers (81%), median age 64 years), with 3037 nonsquamous (69 %) and 1330 squamous tumours (30%). One study evaluated nivolumab + CT (CheckMate 227), four studies evaluated atezolizumab + CT (IMpower 130,131,132 and 150), and three studies pembrolizumab + CT (Keynote 021, 189 and 407). The combination PD-1/PD-L1 inhibitor + CT was significantly associated with improvement of OS (hazards ratio [HR], 0.72; 95% CI 0.61–0.85; p < 0.0001), PFS (HR, 0.63; 95% CI 0.58–0.68; p < 0.0001) and ORR (relative ratio [RR], 2.08; 95% CI 1.69–2.55; p < 0.0001), irrespective of PD-L1 expression level. For patients with low (<1%) or undetectable PD-L1 expression, OS benefit was statistically significant (HR, 0.75; 95% CI 0.63-0.89; p < 0.0008).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      The combination of PD-1/PD-L1 inhibitor to chemotherapy, compared with chemotherapy alone, is associated with significantly improved OS, PFS, and ORR in first-line therapy in NSCLC. This strategy appears as a new standard of care for patients with untreated NSCLC, including for those with low or undetectable PD-L1 expression.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study


      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.